Description

IGF-1 LR3 (Long Arginine 3 Insulin-Like Growth Factor-1) – 1mg

IGF-1 LR3 is a synthetic analog of Insulin-Like Growth Factor-1 (IGF-1) engineered with an arginine substitution at position 3 and an extended 13-amino acid N-terminal sequence. These structural modifications significantly reduce binding affinity to IGF-binding proteins (IGFBPs), resulting in prolonged receptor interaction in laboratory models.

This peptide is designed strictly for laboratory investigation into cellular proliferation pathways, anabolic signaling cascades, and growth factor receptor research.

Purity: >99% (HPLC Tested)
Format: Lyophilized White Powder
Molecular Formula: C400H625N111O115S7
Research Target: IGF-1 Receptor (IGF1R) & PI3K/AKT Signaling Pathway

IGF-1 LR3 binds to the IGF-1 receptor, activating intracellular pathways such as PI3K/AKT and MAPK/ERK. In research models, these pathways are associated with cellular growth, differentiation, and survival signaling. Due to its reduced binding to IGF-binding proteins, IGF-1 LR3 demonstrates extended bioactivity compared to native IGF-1 in controlled laboratory environments.

Research Observed Outcomes

Data from cellular and metabolic research programs highlight the following findings in controlled laboratory models:

Enhanced Cellular Proliferation Signaling:
IGF-1 receptor activation has been shown to stimulate anabolic signaling cascades involved in protein synthesis regulation.

Muscle Cell Differentiation Research:
In vitro studies demonstrate increased myoblast proliferation and differentiation in cultured skeletal muscle cells.

Glucose Uptake Modulation:
Laboratory investigations suggest enhanced glucose transport in muscle cell models through insulin receptor cross-talk pathways.

Reduced Apoptotic Signaling:
IGF-1 pathway activation has been associated with increased cellular survival signaling under stress conditions.

Tissue Regeneration Research:
Experimental models suggest enhanced repair signaling in connective and skeletal tissue systems.

Key Linked Studies & Research References

IGF-1 LR3 Structural Modifications:
Francis, G.L., et al. (1992). “Long R3 IGF-1 analog: reduced binding to IGF-binding proteins.” Journal of Molecular Endocrinology.

IGF-1 Receptor Signaling:
Le Roith, D., et al. (2001). “The insulin-like growth factor system and its role in growth.” Endocrine Reviews.

PI3K/AKT & MAPK Pathways:
Manning, B.D., & Cantley, L.C. (2007). “AKT/PKB signaling: navigating downstream.” Cell.

Muscle Differentiation Research:
Florini, J.R., et al. (1996). “IGF-1 and muscle development.” Journal of Biological Chemistry.

Storage & Stability Protocols

To preserve peptide integrity and structural stability:

Lyophilized Powder:
Store at -20°C for long-term stability. Stable at room temperature for short-term transit.

Reconstituted Stability (Bacteriostatic Water):
When reconstituted under sterile laboratory conditions, solution stability is typically maintained for 4–6 weeks under refrigeration (2°C – 8°C).

Reconstituted Stability (Sterile Water):
Stability is significantly shorter, typically 7–12 days due to absence of antimicrobial preservatives.

Handling:
Avoid repeated freeze-thaw cycles. Protect from excessive heat, light, and agitation during reconstitution.

⚠️ STRICT COMPLIANCE NOTICE: FOR LABORATORY RESEARCH ONLY
This product is a chemical research peptide intended strictly for in vitro or laboratory experimentation. Any form of ingestion, injection, or topical application to humans or animals is STRICTLY PROHIBITED. This product is not a drug, food, or cosmetic and has not been approved by the FDA for any medical application. Handling must be performed by qualified professionals in controlled laboratory environments.